---

Questions 181–200: Jaundice, Hepatitis, Cirrhosis & Liver Cancer

---

181. Classification of Jaundice

I. Prehepatic (Hemolytic / Suprahepatic) Jaundice

• Excess bilirubin production overwhelms hepatic conjugation
• Predominantly unconjugated (indirect) hyperbilirubinemia
• Examples: hereditary spherocytosis, sickle cell disease, thalassemia, G6PD deficiency, autoimmune hemolytic anemia, malaria

II. Hepatic (Parenchymal) Jaundice

• Defect in hepatocyte uptake, conjugation, or excretion
• May present with mixed (both conjugated and unconjugated) hyperbilirubinemia
• Examples: viral hepatitis, alcoholic hepatitis, drug-induced liver injury, cirrhosis, autoimmune hepatitis, inherited disorders (Gilbert's, Crigler-Najjar, Dubin-Johnson, Rotor syndrome)

III. Posthepatic (Mechanical / Obstructive / Subhepatic) Jaundice

• Obstruction of bile flow after bilirubin is conjugated
• Predominantly conjugated (direct) hyperbilirubinemia
• Examples: choledocholithiasis, carcinoma of the pancreatic head, cholangiocarcinoma, biliary strictures, primary sclerosing cholangitis

---

182. Main Causes of Jaundice Syndrome

Prehepatic causes

• Hemolytic anemias (inherited and acquired)
• Ineffective erythropoiesis (B₁₂, folate, iron deficiency)
• Resorption of large hematomas
• Massive blood transfusion

Hepatic causes

• Viral hepatitis (A, B, C, D, E)
• Alcoholic liver disease
• Drug/toxin-induced hepatocellular injury
• Autoimmune hepatitis
• Ischemic hepatitis
• Inherited disorders: Gilbert's syndrome (reduced UGT1A1 activity), Crigler-Najjar syndrome, Dubin-Johnson syndrome, Rotor syndrome
• Infiltrative diseases (lymphoma, sarcoidosis, amyloidosis)

Posthepatic causes

• Choledocholithiasis (common bile duct stones)
• Carcinoma of the pancreatic head
• Cholangiocarcinoma (Klatskin tumor)
• Ampullary carcinoma
• Biliary strictures (post-surgical, inflammatory)
• Primary sclerosing cholangitis
• Chronic pancreatitis causing biliary compression
• Parasitic biliary obstruction

---

183. Diagnostic Criteria for Prehepatic (Hemolytic) Jaundice

---

184. Diagnostic Criteria for Hepatic (Parenchymal) Jaundice

---

185. Diagnostic Criteria for Subhepatic (Mechanical/Obstructive) Jaundice

---

186. Clinical and Laboratory Signs of Jaundice

Clinical Signs

• Icterus — yellowish discoloration of sclera (first visible at bilirubin >2.5–3 mg/dL), skin, mucous membranes
• Pruritus — especially in cholestatic jaundice
• Dark urine (bilirubinuria) — conjugated jaundice
• Pale/acholic stools — obstructive jaundice
• Xanthomas / xanthelasmas — chronic cholestasis
• Hepatomegaly — hepatic or obstructive causes
• Splenomegaly — hemolytic or portal hypertension
• Steatorrhea — chronic bile duct obstruction (fat malabsorption)
• Spider nevi, palmar erythema, leukonychia, caput medusae — chronic liver disease

Laboratory Signs

• Total bilirubin (fractionated into direct/indirect)
• ALT, AST — hepatocellular injury markers
• ALP, GGT — cholestasis markers
• Albumin, prothrombin time — hepatic synthetic function
• CBC — anemia, reticulocytosis in hemolysis
• LDH, haptoglobin — hemolysis markers
• Urinalysis — bilirubinuria, urobilinogen

---

187. Differential Diagnostic Signs of Different Forms of Jaundice

• Prehepatic → indirect bilirubin dominant, no bilirubinuria, ↑ urobilinogen
• Hepatic → mixed bilirubin, markedly elevated transaminases
• Posthepatic → direct bilirubin dominant, absent urobilinogen, ↑ ALP/GGT, dilated bile ducts

---

188. Role of ALT, AST, ALP, and GGT in Differential Diagnosis of Jaundice

ALT (Alanine Aminotransferase)

• Liver-specific enzyme; found in hepatocyte cytoplasm
• Markedly elevated in hepatocellular damage (viral hepatitis, drug injury, ischemic hepatitis)
• ALT > AST suggests viral hepatitis
• AST:ALT ratio >2:1 suggests alcoholic liver disease

AST (Aspartate Aminotransferase)

• Found in liver, heart, muscle, kidney — less specific
• Elevated with ALT in hepatocellular injury
• Isolated AST elevation may indicate myocardial or skeletal muscle damage

ALP (Alkaline Phosphatase)

• Expressed by bile duct epithelium in the liver; also found in bone, intestine, placenta
• Elevated in biliary obstruction (intra- or extrahepatic) — synthesized in excess and released into serum
• Half-life ≈ 7 days; slow normalization after obstruction resolves
• To confirm hepatic origin, check GGT or liver isoenzyme (both elevated = liver source)
• Isolated ALP elevation without GGT suggests bone disease

GGT (Gamma-Glutamyl Transferase)

• Located in hepatocytes and bile duct epithelium
• Most sensitive marker of hepatobiliary disease (but non-specific)
• Induced by: alcohol, certain drugs (phenytoin, barbiturates), pancreatic disease, MI, renal failure
• Elevated GGT + elevated ALP = confirms hepatic source of ALP
• GGT elevated alone (normal ALP) → suspect alcohol use or drug induction

• Hepatocellular injury: ALT/AST >> ALP
• Cholestatic injury: ALP/GGT >> ALT/AST

---

189. Main Biochemical Markers of Cholestasis and Cytolysis

Markers of Cytolysis (Hepatocellular Injury)

Markers of Cholestasis (Impaired Bile Flow)

Markers of Hepatic Synthetic Function

---

190. Instrumental Methods for Diagnosing Jaundice

1. Abdominal Ultrasound (First-line)

• Non-invasive, radiation-free
• Detects: dilated bile ducts (obstructive jaundice), gallstones, hepatomegaly, liver texture changes, masses
• Limitation: poor visualization of distal common bile duct (bowel gas)

2. CT Scan (Computed Tomography)

• Better visualization of biliary tree, pancreas, portal vein
• Identifies: pancreatic head masses, cholangiocarcinoma, hepatic metastases, lymphadenopathy
• With contrast: defines vascular anatomy

3. MRCP (Magnetic Resonance Cholangiopancreatography)

• Non-invasive "roadmap" of the biliary tree
• Gold standard for diagnosing bile duct strictures, choledocholithiasis, primary sclerosing cholangitis
• No radiation, no contrast required

4. ERCP (Endoscopic Retrograde Cholangiopancreatography)

• Diagnostic and therapeutic — allows sphincterotomy, stone extraction, stent placement
• Used when MRCP confirms obstruction requiring intervention
• Risk of pancreatitis, cholangitis, perforation

5. PTC (Percutaneous Transhepatic Cholangiography)

• Alternative when ERCP not feasible
• Can place external/internal biliary drains

6. Liver Biopsy

• Definitive for hepatocellular jaundice when etiology unclear after serologic testing
• Transjugular approach preferred in coagulopathy
• Guides diagnosis of autoimmune hepatitis, PBC, PSC, storage diseases, malignancy

7. Endoscopic Ultrasound (EUS)

• High-resolution imaging of distal bile duct and pancreatic head
• Allows fine-needle aspiration of masses

---

191. Classification of Chronic Hepatitis

By Etiology

1. Chronic viral hepatitis — HBV (±HDV), HCV
2. Autoimmune hepatitis — Types 1, 2, 3
3. Drug-induced chronic hepatitis — isoniazid, methyldopa, nitrofurantoin
4. Metabolic/genetic — Wilson's disease, alpha-1 antitrypsin deficiency, NAFLD/NASH
5. Cryptogenic — no identifiable cause

By Histological Grade & Stage (Knodell/METAVIR scoring)

• Grade (activity): degree of necroinflammation (0–4 or A0–A3)
• Stage (fibrosis): F0 (none) → F1 (portal fibrosis) → F2 (periportal) → F3 (bridging) → F4 (cirrhosis)

Traditional Histological Classification (older terminology, still used clinically)

• Chronic Persistent Hepatitis (CPH) — mild, portal inflammation, preserved lobular architecture, no necrosis; generally benign prognosis
• Chronic Active (Aggressive) Hepatitis (CAH) — periportal inflammation, piecemeal necrosis (interface hepatitis), progressive fibrosis; risk of cirrhosis
• Chronic Lobular Hepatitis — predominantly lobular necroinflammation

---

192. Diagnostic Criteria for Chronic Persistent Hepatitis (CPH)

Clinical Features

• Often asymptomatic or mild fatigue, right upper quadrant discomfort
• No signs of hepatic decompensation (no jaundice, ascites, encephalopathy)
• Mild or no hepatomegaly

Laboratory Features

• Mild elevation of transaminases (ALT 1.5–3× ULN)
• Normal or near-normal albumin and PT
• Normal or mildly elevated bilirubin
• Specific serological markers depending on etiology (anti-HCV, HBsAg, ANA, etc.)

Histological Criteria (definitive)

• Portal inflammation confined to portal tracts
• Intact limiting plate (no interface hepatitis / piecemeal necrosis)
• Normal lobular architecture preserved
• Minimal or no fibrosis (F0–F1)
• Absence of bridging necrosis

Prognosis

• Generally benign; does not commonly progress to cirrhosis
• Regression possible with treatment of underlying cause (antiviral therapy, cessation of offending drug)

---

193. Principles of Treatment of Chronic Hepatitis

General Measures

• Remove/treat underlying cause (antiviral therapy, alcohol cessation, stop offending drugs)
• Avoid hepatotoxins (alcohol, certain medications)
• Vaccination against HAV and HBV if not immune
• Nutritional support

Viral Hepatitis B

• Tenofovir (TDF or TAF) or Entecavir — first-line oral antivirals
• Pegylated interferon-alfa — finite course, achieves HBsAg seroconversion in some patients
• Goal: suppress HBV DNA, normalize ALT, prevent fibrosis progression

Viral Hepatitis C

• Direct-acting antivirals (DAAs) — pangenotypic regimens: sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
• Sustained virologic response (SVR = "cure") in >95% of patients
• 8–12 week courses

Autoimmune Hepatitis

• Prednisolone ± Azathioprine — standard induction and maintenance
• Budesonide as alternative in non-cirrhotic patients
• Mycophenolate mofetil for azathioprine-intolerant patients

NAFLD/NASH

• Weight loss (>7–10% body weight), exercise, metabolic optimization
• Control of diabetes, hyperlipidemia, hypertension
• Emerging pharmacotherapy: resmetirom, semaglutide (under evaluation)

Monitoring

• Regular LFTs, viral loads, AFP surveillance in HBV/HCV
• Fibrosis reassessment (elastography, APRI, FIB-4)
• Screen for hepatocellular carcinoma in advanced fibrosis/cirrhosis

---

194. Differential Diagnosis of Cirrhosis and Liver Cancer

---

195. Complications of Liver Cirrhosis

1. Portal Hypertension → variceal bleeding (esophageal, gastric), portal hypertensive gastropathy
2. Ascites — most common decompensation event; cirrhosis accounts for ~84% of cases
3. Spontaneous Bacterial Peritonitis (SBP) — infection of ascitic fluid (PMN >250/mm³)
4. Hepatic Encephalopathy — neuropsychiatric dysfunction from ammonia and other toxins; 20–40% 1-year survival after onset
5. Hepatorenal Syndrome (HRS) — functional renal failure; HRS-1 (acute, severe) and HRS-2 (chronic)
6. Hepatocellular Carcinoma (HCC) — annual incidence 1–8% in cirrhotic patients
7. Coagulopathy — decreased synthesis of clotting factors, thrombocytopenia (hypersplenism)
8. Hepatopulmonary Syndrome — intrapulmonary vascular dilatations → hypoxemia
9. Portopulmonary Hypertension — elevated pulmonary artery pressure
10. Malnutrition and Sarcopenia
11. Hyponatremia — dilutional, due to ADH dysregulation

---

196. Basic Laboratory Parameters in Liver Cirrhosis

---

197. Instrumental Diagnostics of Liver Cirrhosis

1. Abdominal Ultrasound

• First-line: nodular liver surface, increased echogenicity, caudate lobe hypertrophy
• Portal vein diameter >13 mm (portal hypertension)
• Splenomegaly, ascites, collateral vessels

2. Doppler Ultrasound

• Assesses portal blood flow direction (hepatofugal flow = severe portal hypertension)
• Detects portal vein thrombosis

3. CT / MRI

• Detailed liver morphology, HCC surveillance, vascular anatomy
• Dynamic contrast MRI — arterial enhancement of HCC nodules

4. Transient Elastography (FibroScan)

• Non-invasive fibrosis staging by measuring liver stiffness (kPa)
• Cirrhosis: >12.5 kPa (varies by etiology)
• Alternative non-invasive indices: APRI, FIB-4

5. Upper GI Endoscopy (Esophagogastroduodenoscopy)

• Identifies esophageal and gastric varices
• Grades variceal size; guides prophylactic banding or beta-blocker therapy

6. Liver Biopsy (Gold Standard for Histology)

• Confirms diagnosis, grades activity, stages fibrosis
• Transjugular approach preferred in coagulopathy (also measures hepatic venous pressure gradient — HVPG)

7. HVPG (Hepatic Venous Pressure Gradient)

• 5 mmHg = portal hypertension; >10 mmHg = clinically significant; >12 mmHg = variceal bleeding risk

---

198. Modern Principles of Liver Cirrhosis Therapy and Prognosis Criteria

Treatment Principles

• HBV/HCV: antiviral therapy (can lead to fibrosis regression)
• Alcohol: complete abstinence
• NASH: weight loss, metabolic management
• Autoimmune hepatitis: immunosuppression
• Wilson's disease: copper chelation (D-penicillamine, trientine)

• Ascites: salt restriction (<2 g/day), diuretics (spironolactone ± furosemide), therapeutic paracentesis, TIPS
• Variceal prophylaxis: non-selective beta-blockers (propranolol, carvedilol) or endoscopic band ligation
• SBP: IV ceftriaxone/cefotaxime; prophylaxis with norfloxacin in high-risk patients
• Hepatic encephalopathy: lactulose (target 2–3 soft stools/day), rifaximin, identify and treat precipitants
• HRS: vasoconstrictors (terlipressin + albumin); renal replacement therapy

• Indicated in decompensated cirrhosis (MELD ≥15), HCC within Milan criteria
• Milan criteria for HCC: single lesion ≤5 cm OR up to 3 lesions each ≤3 cm, no vascular invasion

Prognosis Criteria

• Parameters: serum bilirubin, albumin, PT, degree of ascites, grade of encephalopathy
• Class A: 5–6 pts (1-year survival ~100%); Class B: 7–9 pts; Class C: 10–15 pts (1-year survival ~45%)

• Formula: 3.78×ln[bilirubin mg/dL] + 11.2×ln[INR] + 9.57×ln[creatinine mg/dL] + 6.43
• Range 6–40; higher = greater 3-month mortality
• Used for transplant waiting list prioritization

---

199. Modern Methods of Laboratory and Instrumental Diagnostics of Liver Cancer

Laboratory Methods

Instrumental Methods

---

200. Principles of Treatment for Primary and Secondary Liver Cancer

Primary Liver Cancer (Hepatocellular Carcinoma — HCC)

• Surgical resection — single tumor, adequate hepatic reserve (Child-Pugh A), no portal hypertension
• Liver transplantation — within Milan criteria; removes tumor and underlying cirrhosis
• Radiofrequency ablation (RFA) / Microwave ablation (MWA) — tumors ≤3 cm, not surgically resectable; curative intent

• TACE (Trans-Arterial Chemo-Embolization) — standard for BCLC-B (multinodular, preserved liver function, no vascular invasion)
• TARE (Trans-Arterial Radio-Embolization with Y-90 microspheres) — alternative to TACE

• Sorafenib (multikinase inhibitor) — first approved systemic therapy
• Lenvatinib — non-inferior to sorafenib, first-line alternative
• Atezolizumab + Bevacizumab — current preferred first-line regimen (immunotherapy + VEGF inhibition; superior OS vs sorafenib)
• Tremelimumab + Durvalumab — alternative first-line option
• Second-line: regorafenib, cabozantinib, ramucirumab (AFP >400)

Secondary Liver Cancer (Metastases)

• Surgical resection — gold standard when technically feasible, adequate liver remnant
• Perioperative chemotherapy — FOLFOX/FOLFIRI ± bevacizumab/cetuximab
• Ablative techniques (RFA, MWA) — for small, unresectable lesions
• TACE / TARE — for chemorefractory, unresectable disease

• Primary systemic chemotherapy based on tumor origin
• Surgery rarely curative except neuroendocrine tumors (NET) metastases — resection and PRRT (peptide receptor radionuclide therapy)
• Liver-directed therapy as palliative adjunct

• Resection when possible (R0 margin critical)
• Gemcitabine + cisplatin — standard first-line systemic chemotherapy
• Pemigatinib / Infigratinib — for FGFR2 fusion-positive intrahepatic cholangiocarcinoma (targeted therapy)
• Pembrolizumab — for MSI-H/dMMR tumors
• ERCP/PTC biliary drainage for obstructive jaundice

---